Tips From Other Journals - American Family Physician

December 1, 2009 Table of Contents

Tips from Other Journals

Treating Bell Palsy: Steroids, Not Antivirals

Am Fam Physician. 2009 Dec 1;80(11):1304-1306.

Background: Treating Bell palsy (idiopathic facial paralysis) remains problematic because an optimal therapy has not been established. Corticosteroids are the most widely accepted treatment; however, antivirals are also often used because herpes simplex virus (HSV) has been isolated from the facial nerve endoneurial fluid of some affected patients. There are conflicting reports whether combining antivirals with corticosteroids is more effective than monotherapy. Goudakos and Markou attempted to clarify which treatment option would provide the best results.

The Study: The authors conducted a meta-analysis of randomized controlled trials examining clinical outcomes with Bell palsy. All studies compared corticosteroid therapy versus combined corticosteroid and antiviral treatment, with at least three months of follow-up. Studies were excluded if they included patients with uncontrolled diabetes mellitus, peptic ulcer disease, suppurative otitis media, herpes zoster, multiple sclerosis, pregnancy, or systemic infection. The primary outcome was complete recovery of facial motor function three months after starting therapy.

Results: The authors reviewed five studies that included a total of 738 patients. All studies used prednisolone or deflazacort (not available in the United States) as the corticosteroid, and acyclovir (Zovirax) or valacyclovir (Valtrex) as the antiviral agent. Meta-analysis of available data showed no difference at three months in complete recovery rates between the corticosteroid group and the combined therapy group (odds ratio [OR] = 1.03, P = .88). No difference in recovery occurred between valacyclovir and acyclovir. Individual study data also showed no difference between the corticosteroid group and the combined therapy group in complete recovery at four, six, or nine months after initiating treatment. Initiating treatment within three days (versus seven days) of disease onset did not affect recovery rates. Adverse effect rates were also similar between treatment groups.

Conclusion: Adding an antiviral agent to corticosteroids for treating Bell palsy does not result in better recovery rates of facial motor function. The authors state that these findings do not justify the addition of an antiviral in this situation, but that further trials are needed to more confidently assess the potential value of antiviral medications in the treatment of Bell palsy.

KENNETH T. MOON, MD

Source

Goudakos JK, Markou KD. Corticosteroids vs corticosteroids plus antiviral agents in the treatment of Bell palsy: a systematic review and meta-analysis. Arch Otolaryngol Head Neck Surg. June 2009;135(6):558–564.

editor's note: With true (i.e., idiopathic) Bell palsy, there is no reason to believe that antivirals might improve symptoms. The real question is whether they might be useful for the roughly one third of patients thought to have Bell palsy whose symptoms are attributed to HSV, or varicella-zoster virus (VZV) without cutaneous lesions (zoster sin herpete).1,2 This meta-analysis did not separately examine this subgroup. However, its findings are in line with other studies3–5 that found no added benefit of antivirals in the larger Bell palsy population, despite the large presumed included subgroup of HSV- or VZV-affected patients. One study specifically examining this subgroup also reported no benefit of adding valacyclovir to a corticosteroid.2 Regardless of whether HSV or VZV may underlie a Bell palsy case, the evidence favors corticosteroid monotherapy for treatment.

A Cochrane Review also showed no definitive benefit of adding antivirals to corticosteroids for Ramsay Hunt syndrome (herpes zoster oticus),6 which presents with similar facial paralysis and zoster lesions in or around the ear canal. However, these findings relied on one small, low-quality study. At least for Ramsay Hunt syndrome, many physicians may be more comfortable using combination therapy until further evidence is available.—k.t.m.

REFERENCES

1. Furuta Y, Ohtani F, Kawabata H, Fukuda S, Bergström T. High prevalence of varicella-zoster virus reactivation in herpes simplex virus–seronegative patients with acute peripheral facial palsy. Clin Infect Dis. 2000;30(3):529–533.

2. Kawaguchi K, Inamura H, Abe Y, et al. Reactivation of herpes simplex virus type 1 and varicella-zoster virus and therapeutic effects of combination therapy with prednisolone and valacyclovir in patients with Bell's palsy. Laryngoscope. 2007;117(1):147–156.

3. Sullivan FM, Swan IR, Donnan PT, et al. Early treatment with prednisolone or acyclovir in Bell's palsy. N Engl J Med. 2007;357(16):1598–1607.

4. Engström M, Berg T, Stjernquist-Desatnik A, et al. Prednisolone and valaciclovir in Bell's palsy: a randomised, double-blind, placebo-controlled multicentre trial. Lancet Neurol. 2008;7(11):993–1000.

5. Yeo SG, Lee YC, Park DC, Cha CI. Acyclovir plus steroid vs steroid alone in the treatment of Bell's palsy. Am J Otolaryngol. 2008;29(3):163–166.

6. Uscategui T, Dorée C, Chamberlain IJ, Burton MJ. Antiviral therapy for Ramsay Hunt syndrome (herpes zoster oticus with facial palsy) in adults. Cochrane Database Syst Rev. 2008;(4):CD006851.

Copyright © 2009 by the American Academy of Family Physicians.
This content is owned by the AAFP. A person viewing it online may make one printout of the material and may use that printout only for his or her personal, non-commercial reference. This material may not otherwise be downloaded, copied, printed, stored, transmitted or reproduced in any medium, whether now known or later invented, except as authorized in writing by the AAFP. Contact afpserv@aafp.org for copyright questions and/or permission requests.